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Abstract: 
In recent years the availability of so called legal highs over the 
internet has hugely increased. Numerous online legal high retailers 
market a broad variety of products which are advertised as 
research chemicals, bath salts or plant food although clearly 
intended for human consumption as recreational drug 
replacements. No guidelines exist as to what is sold and in what 
purity. Consumers are led to believe that purchased goods are 
entirely legal. 
In this study several legal high products were purchased and 
analysed for their content. The powdered products were screened 
with ATR-FTIR followed by GC-MS analysis of methanol extracts. 
Spectra were compared to reference standards and the NIST 
library. 
Results showed that 6 out of 7 products did not contain the 
advertised active ingredient. Moreover, five samples contained the 
controlled substances benzylpiperazine and 1-[3-
(trifluoromethyl)phenyl]piperazine combined with caffeine. 
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TITLE 
Analysis of legal highs – do they contain what it says on the tin? 
 
ABSTRACT 
In recent years the availability of so called legal highs over the internet has hugely 
increased. Numerous online legal high retailers market a broad variety of products 
which are advertised as research chemicals, bath salts or plant food although clearly 
intended for human consumption as recreational drug replacements. No guidelines 
exist as to what is sold and in what purity. Consumers are led to believe that 
purchased goods are entirely legal. 
In this study several legal high products were purchased and analysed for their 
content. The powdered products were screened with ATR-FTIR followed by GC-MS 
analysis of methanol extracts. Spectra were compared to reference standards and the 
NIST library. 
Results showed that 6 out of 7 products did not contain the advertised active 
ingredient. Moreover, five samples contained the controlled substances 
benzylpiperazine and 1-[3-(trifluoromethyl)phenyl]piperazine combined with 
caffeine. 
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INTRODUCTION 
There has been a recent explosion in the number of substances that can be purchased 
from the internet marketed as legal highs. A survey on internet availability published 
in April 2009 found 39 individual UK online legal high retailers selling a total of 
1308 products [1]. These substances are sold as ‘not for human consumption’ and for 
a variety of uses such as research chemicals, plant food and bath salts but it is clear 
that they are intended for human consumption and that the intended market is as a 
replacement for either MDMA or cannabis in the recreational drugs scene. In fact 
recent figures suggest that there has been a decrease in the use of MDMA with the 
suggestion that this is not due to a decrease in recreational drug use but simply a 
switch to more readily available legal highs [2]. The term legal high carries with it a 
perception of safety and acceptability and although many of the compounds 
advertised as being the active ingredient in the currently marketed products are not 
controlled, many of these have as yet not been tested on humans and the purity of the 
products are unknown. This is an unregulated area and is simply being driven by the 
market.  
 
2009 and 2010 saw a significant increase in legislation in the UK to try and curb the 
availability and use of legal highs with a number of Misuse of Drugs Act modification 
orders.  These controlled a number of cathinones [3] including the much publicised 4-
methylmethcathinone (mephedrone), piperazines, and synthetic cannabinoids [3,4] 
using generic controls. On the face of it these controls have been effective in 
removing products claiming to contain these substances from website retailers 
however it has been seen that so called new legal products do in fact contain 
controlled substances [5]. Analysis of 24 products claiming to be legal purchased 
from 18 UK-based websites obtained in a six week period following the April 2010 
ban of cathinones revealed that 62.5% of the products contained these controlled 
substances [6]. Clearly this is unknown to the user and may well be to the online 
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2 
retailer. Users are left to evaluate new substances on their experience of use and 
through communicating their experiences in online fora.   
 
As substances are controlled then new substances quickly appear and are marketed 
as being better than previous products. The synthesis of many of the active ingredients 
of these second generation legal highs such as 5,6-methylenedioxy-2-aminoindane 
(MDAI), 5-iodo-2-aminoindane (5-IAI) and 6-(2-aminopropyl)benzofuran (6-APB) 
(figure 1) have been previously published [7,8,9] however little is known about their 
effects on humans. Another problem highlighted is that substances labelled as the 
same product may in fact be structural isomers of the expected active ingredient 
which are unknown within the literature [10]. 
 
There is also little reported on methods of analysis for these new compounds with a 
need to use techniques not routinely used in forensic drugs labs such as NMR and 
high-resolution mass spectrometry [11]. This is due to the lack of good quality 
reference standards required by routine analytical methods to update spectroscopic 
databases and for calibration. Some are available [12] but these tend to be expensive 
for a few mgs and a full range for current products is not available. Identification of 
previously unreported cathinones was possible as a follow-up to the study carried out 
in [6] because the authors were able to synthesise the reference standards required 
[13]. 
 
We report here the analysis of legal highs purchased in the second half of 2010 from 
several internet sites using a standard approach of FTIR and GC-MS of methanol 
extracts. We were interested in the chemical composition of these products to test the 
previous findings that legal high products are not always what they are advertised to 
be. We were also interested in seeing if these products are in fact illegal as reported in 
previous investigations and so suppliers and users would be committing an offence 
even if they were ignorant of this fact.  
  
MATERIALS AND METHODS 
 
 Chemicals and materials 
5,6-Methylenedioxy-2-aminoindane was purchased from LGC GmbH (Luckenwalde, 
Germany), 1-(2-Trifluoromethylphenyl) piperazine and 1-(4-Trifluoromethylphenyl) 
piperazine from FluoroChem (Hadfield, UK), mephedrone from ReseaCHEM 
(Burgdorf, Switzerland) and caffeine from Sigma-Aldrich (Gillingham, UK). 
Methanol (HPLC-grade) was obtained from Fisher Scientific (Loughborough, UK). 
Chemical structures are shown in Figure 1. 
Four legal high samples were purchased online in August 2010 as MDAI, 5-IAI, 
Benzo Fury and NRG-3 including a free sample of E2 from www.benzofury.me.uk; 
two more MDAI labelled samples were purchased in October 2010 from 
www.VIPlegals.com and www.wide-mouth-frog.com (Table 1). 
 
 FTIR conditions 
Fourier-transform infrared spectroscopy (FTIR) was performed on a Perkin Elmer 
Spectrum 100 FT-IR spectrometer using the attenuated total reflectance (ATR) 
attachment (Specac Golden Gate). The instrument was operated with Perkin Elmer 
Spectrum software (2006). The scan range was 4000 – 450 cm-1 with a scan number 
of 64, a resolution of 4 cm-1 and a scan speed of 0.5 cm s-1.  
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3 
Standards and samples were applied in their powdered form. Spectra were 
compared to an in-house drugs library which contained a range of drugs of abuse and 
legal highs apart from 5-IAI and 6-APB as genuine standards were not available at the 
time of analysis. Finally, a cross correlation of all internet samples was performed 
using the Euclidean algorithm. 
 
Sample preparation for GC-MS 
All standards were prepared in methanol at concentrations ranging between 0.1 and 1 
µg mL-1 and filtered through 0.45 µm pore size syringe filters from Chromacol (Herts, 
UK) prior to injection. 
The legal high samples were extracted into methanol at a concentration of 10 mg 
powder per 1 mL methanol. After vortexing for 1 minute the samples were 
centrifuged at 4000 rpm for 2 minutes using a Beckman Coulter Allegra X-22 
centrifuge. The supernatant was filtered through Chromacol syringe filters with a pore 
size of 0.45 µm. Samples were diluted 1000 times in methanol prior injection. 
 
 GC-MS conditions 
Gas chromatography was performed using a Perkin Elmer Clarus 600 Gas 
Chromatograph equipped with an autosampler. Standards and samples were run on an 
Agilent Technologies DB-1MS column (30 m x 0.25 mm x 0.25 µm). The oven 
temperature program was an initial 4 minute plateau at 150 oC increasing to a final 
temperature of 350oC at 32 °C min-1 giving a total run time of 10.25 min. The 
temperature programmable injector port was held at 250 °C for 4 minutes and then 
increased to 300 °C at 50 °C min-1. The final temperature was held for 5.25 minutes to 
correlate with the total run time of 10.25 minutes. The carrier gas was helium at 1 
mLmin-1 with vacuum compensation and the injection volume was 1 µL. 
Mass spectrometry was performed using a Perkin Elmer Clarus 600 Mass 
Spectrometer operated with Perkin Elmer TurboMass (2008) software. The transfer 
line temperature was held at 300 °C. Positive ionisation was achieved using an 
Electron Impact (EI+) source at 200 °C with electron energy of 70 eV. The multiplier 
was set to 300 V. After 2 minutes solvent delay the peaks were observed in total ion 
count (TIC) mode. The scan range was 40 – 300 m/z with 1 scan per second and an 
interscan delay of 0.01 s. Mass spectra of selected peaks were compared to the 
National Institute of Standard and Technology library (TurboMass NIST 2008 
Library, version 2.2.0) and in-house run reference standards. 
 
 
RESULTS & DISCUSSION 
 
Samples obtained from the benzofury.me.uk site were white powders in simple plastic 
re-sealable bags. The content was marked in black felt-tip pen on the bag as the 
abbreviations MDAI, 5IAI and NRG3. The benzo fury product was contained in two 
capsules. No other information was provided. The MDAI product obtained from 
www.wide-mouth-frog.com was a white powder in a metallic sealed bag. The full 
name was given along with the warnings ‘Strictly not for human consumption’ and ‘1 
g feeds 10 plants’.  The MDAI product obtained from www.VIPlegals.com was also a 
white powder in a re-sealable plastic bag. A printed label was attached to the bag with 
the abbreviation MDAI and a warning ‘Not for Human Consumption’. An 
accompanying certificate of analysis sheet was also provided giving the full name of 
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4 
the product as 5,6-methylenedioxy-2-aminoindane hydrochloride and giving a purity 
as measured by HPLC of 99.55%.  
  
 FTIR studies 
The legal high reference standards and internet bought samples were screened using 
ATR-FTIR and a search carried out against an in-house drugs of abuse library. 
 
These results showed that the benzofury.me.uk products all appeared to contain 
caffeine which was the best match found in the library for all the spectra (Table 2). 
The difference spectra obtained by subtraction of the caffeine spectrum from each of 
these product spectra did not result in any subsequent library matches. This was 
expected for the 5-IAI and benzo fury products as the active ingredients, 5-IAI and 6-
APB (the active ingredient in benzo fury) were not in the library due to unavailability 
of the standards. However it was expected that the MDAI product would match with 
the MDAI standard spectrum (Figure 2). This was not the case suggesting this product 
did not contain the advertised active ingredient at least as a major constituent. Care 
was taken in interpreting the FTIR spectral data as it can be difficult to detect 
substances in mixtures below about 10%. When comparing the spectra of MDAI and 
caffeine it can be seen that caffeine as the major component in a mixture would 
almost completely obscure the spectrum of MDAI except for the 3345, 3288 
(corresponding to the N-H stretch of the aliphatic primary amine), 1143 (related to the 
C-O stretch of the alkyl substitut d ether C-O-C) and 944 cm-1 (resulting from one of 
the aromatic C-H in-plane bends) peaks (Figure 2) [14]. Despite these features being 
unique to MDAI when compared to caffeine, a 10% MDAI mixture in caffeine gave a 
library search result of 0.995 for caffeine proving these MDAI-only featured peaks 
were not strong enough for the MDAI to be picked-up by the algorithm.  
 
The sample from VIPlegals.com gave a good match with MDAI indicating that this 
was a genuine product at least in that it contain d the active ingredient as advertised. 
This was not the case with the product from wide-mouth-frog.com which had a poor 
correlation and gave a similar match to caffeine observed with the benzofury.me.uk 
products. The E2 free sample gave the best match with caffeine although this does not 
demonstrate the absence of any active ingredient as discussed earlier. Correlations are 
summarised in Table 2. 
 
Cross-correlation of the benzofury.me.uk products all appeared to be well matched 
as do these products with the wide-mouth-frog.com MDAI product (Table 3). This 
suggests that the same mixture was simply being sold as different products and that 
although the new legal high products are being actively marketed by internet retailers 
they aren’t necessarily the products that are being sold. It also suggests that different 
internet retailers are selling the same mixtures as the same or different advertised 
products. This may point to the fact that retailers are simply packaging samples and 
are not blending mixtures.  
 
 GC-MS studies 
Gas chromatography coupled with mass spectrometry was used to separate the 
various compounds present in the legal high samples and to identify any active 
ingredients present. The methanol extracts were injected underivatised into a 
temperature programmable injector port where the initial temperature 250°C was held 
Page 4 of 17
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
5 
constant to accommodate the plateau in the oven program but then ramped up to 
300°C to ensure full vaporisation of the injected sample. 
Retention times and mass spectra profiles of the standards MDAI, mephedrone, 2-
TFMPP, 4-TFMPP and caffeine were established (Table 4). Caffeine did not elute as 
a sharp peak but tailed off and merged into the column bleeding which expectedly 
occurred towards the end of the run. The molecular ion peak for mephedrone could 
not be seen due to high ionisation energies applied.  
After analysis of the seven online purchased legal high samples, chromatograms 
were scrutinised for peaks which matched retention times with the tested standards. 
Mass spectra profiles of these peaks were compared to the standards to ensure correct 
identification. Unidentified peaks were searched through the NIST library (Table 5). 
Finally, ions of known psychoactive substances (legal and illegal) were extracted 
from the recorded TIC spectra. 
Results showed that only one sample contained the label described substance 
(MDAI), all other samples contained caffeine in a mix of BZP and 3-TFMPP. 
Although quantitative work was not carried out in this study the relative amounts 
(based on peak areas) of the two piperazines were similar suggesting a similar 
product. This confirmed the FTIR results.  
The inaccuracy of product labels has been reported by other chemical analysis 
studies of internet products [5,6]. Of interest is that an MDAI product was analysed in 
both of these studies. In one product the active ingredient was found to be the 
controlled substance methylone whereas the other product simply consisted of 
inorganic material. This is consistent with our results that show MDAI was the active 
ingredient in one product but that the MDAI label was also used as a cover for other 
substances, which maybe controlled.  
The free sample labelled ‘E2’ simply consisted of caffeine as an active ingredient 
and so suggests the absence of other low concentration active ingredients that could 
not be ruled out by FTIR alone. 
At the time of this study we did not have a 3-TFMPP standard which is the 
controlled psychoactive isomer sold in internet products however the mass spectrum 
was available in the NIST database. Identification of 3-TFMPP in the products was 
achieved by comparing retention times of the non-psychoactive isomers 2-TFMPP 
and 4-TFMPP combined with a NIST library search of the mass spectra in question. 
The library matched the unknown peak at 5.3 minutes to 3-TFMPP. All mass spectra 
of the three structural isomers appeared similar but retention times varied greatly with 
peaks being perfectly separated at 4.8 minutes for 2-TFMPP, 5.3 minutes for 3-
TFMPP and 5.7 minutes for 4-TFMPP therefore allowing a definitive identification of 
the 3-isomer. This highlights the importance of the GC separation and use of retention 
times when discriminating between structural isomers with similar mass spectra [10]. 
The combination of BZP and 3-TFMPP is not unusual as it is commonly found in 
party pills under names such as Charge and Bliss depending on the relative amounts 
[15].  
The MDAI MS was not in the NIST database however it was determined from the 
commercial standard (Figure 5) which showed an expected molecular ion with m/z 
177.087 with its corresponding isotope with m/z 178.100, their relative abundance 
matching closely the expected natural occurrences of 89.01% and 9.99% respectively. 
The base peak was m/z 160.051 which corresponds to a loss of NH3 from the 
molecular ion (Table 4). 
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6 
It was established that 5-IAI and APB were not present in the products in which they 
were expected by a selected ion search for their respective molecular ions of m/z 259 
and 174 (figure 1). 
It is possible that non-volatile active ingredients could also be present in these 
products and so a derivatisation method with GC-MS or further analysis using LC-MS 
might yield more ingredients. 
 
CONCLUSIONS 
 
Seven samples were purchased online as legal highs and characterised by FTIR and 
GC-MS. The FTIR study revealed that 6 out of 7 samples did not contain the claimed 
drug but large quantities of caffeine. The presence of large amounts of caffeine was 
confirmed by GC-MS. Moreover, it was found that only one of the purchased samples 
contained MDAI as claimed. Five samples were a mixture of the controlled 
substances BZP and 3-TFMPP combined with caffeine. As BZP and 3-TFMPP are  
both controlled substances, users of these internet products are in possession of illegal 
substances having purchased them assuming them to be legal. Another issue of 
concern, previously highlighted by others, is the lack of consistency between products 
of the same name. If purchasers use different suppliers for the same named product it 
is also highly likely that they could be using products with different active 
ingredients.  
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8 
Figure captions: 
 
Figure 1 
Chemical structures of selected legal high related substances 
 
Figure 2 
FTIR spectra of (a) caffeine and (b) MDAI 
 
Figure 3 
FTIR spectra of (a) MDAI LGC standard, (b) Benzofury.me.uk sample, (c) Wide-
mouth-frog.com sample, and (d) VIPlegal.com sample 
 
Figure 4 
Extracted chromatograms of (a) MDAI standard and (b) VIPlegal.com sample (m/z 
177, 160, 149, 130, 91). (c) EI+ mass spectrum of MDAI and related molecular ion 
and base peak chemical structures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Overview of analysed legal high samples 
 
Date purchased Product Price Expected active ingredient 
MDAI 
(Benzofury.me.uk) £ 14.50 per 1 g 
5,6-Methylenedioxy-2-
aminoindane 
5-IAI £ 26.99 per 2 g 5-Iodo-2-aminoindane 
Benzo fury £ 16.00 per 2 
pellets 
6-(2-aminopropyl)benzofuran 
(6-APB) 
NRG-3 £ 27.99 per 2 g n/a 
August 2010 
E2 free n/a 
MDAI 
(VIPlegal.com) £ 15.00 per 1 g 
October 2010 
MDAI 
(Wide-mouth-frog.com) 
£ 15.00 per 1 g 
5,6-Methylenedioxy-2-
aminoindane 
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Table 2: Results of FTIR search of in-house drugs library 
 
Internet Product Library Search Results 
5-IAI Caffeine 0.635 
Benzo fury Caffeine 0.681 
NRG-3 Caffeine 0.648 
E2 Caffeine 0.996 
MDAI (Benzofury.me.uk) Caffeine 0.677 
MDAI (VIPlegal.com) MDAI 0.723 
MDAI (Wide-mouth-frog.com) Caffeine 0.617 
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Table 3: Correlation table of the FTIR spectra of all internet products 
 
 5-IAI Benzo 
fury 
NRG-
3 
E2 MDAI 
(Benzo 
fury.me.uk) 
MDAI 
(VIPlegal.com) 
MDAI 
(Wide-
mouth-
frog.com) 
5-IAI - 0.9977 0.9980 0.5824 0.9974 0.0629 0.9705 
Benzo fury 0.9977 - 0.9975 0.6219 0.9990 0.0618 0.9668 
NRG-3 0.9980 0.9975 - 0.5953 0.9975 0.0654 0.9625 
E2 0.5824 0.6219 0.5953 - 0.6125 0.0569 0.5520 
MDAI 
(Benzo 
fury.me.uk) 
0.9974 0.9990 0.9975 0.6154 - 0.0635 0.9659 
MDAI 
(VIPlegal.com) 0.0629 0.0618 0.0654 0.0569 0.0635 - 0.0463 
MDAI 
(Wide-mouth-
frog.com) 
0.9705 0.9668 0.9625 0.5520 0.9659 0.0463 - 
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Table 4. Key ions for the compounds of interest for this study 
 
Compound Retention time 
(min) 
EI+ generated ions 
(m/z) 
Mephedrone 4.7 147, 119, 58 (base peak) 
2-TFMPP 4.8 230 (molecular ion), 188 (base peak) 
4-TFMPP 5.7 230 (molecular ion), 211, 188 (base peak) 
MDAI 5.7 177 (molecular ion), 160 (base peak), 149, 130, 91 
Caffeine 7.1 194 (molecular ion and base peak), 109, 82, 67, 55 
BZP1 5.0 176 (molecular ion), 91 (base peak), 134 
3-TFMPP1 5.3 230 (molecular ion), 188 (base peak) 
1
 Identified by NIST library, retention times deduced from the products 
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Table 5: Overview of GC-MS results of internet bought legal high samples 
 
Product Active 
substances 
identified 
Product Active 
substances 
identified 
MDAI 
(Benzofury.me.uk) 
BZP 
3-TFMPP 
Caffeine 
Benzo 
fury 
BZP 
3-TFMPP 
Caffeine 
MDAI  
(VIPlegals.com) 
MDAI 5-IAI BZP 
3-TFMPP 
Caffeine 
NRG-3 BZP 
3-TFMPP 
Caffeine 
MDAI  
(Wide-mouth-frog.com) 
BZP 
3-TFMPP 
Caffeine 
 
E2 Caffeine 
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